← Leaderboards
Gino A Cortopassi
University Of California At Davis
$15,898,234
Attributed
$17,220,122
Total exposure
18
Grants
17
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4M · FY2008–23$5M$3.8M$2.5M$1.3M$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$39,318,365 · 20
By mechanism
P01$28,722,379 · 10
R01$7,147,793 · 4
R21$1,604,062 · 3
R56$783,430 · 1
R41$634,071 · 1
R33$426,630 · 1
Top collaborators
- Natalie J Torok5 shared
- Jon J. Ramsey1 shared
Most similar at University Of California At Davis
Same institution · by research overlap
- James E Evans$24,548,395
- Christopher John Murphy$14,149,626
- Sanjeevi Sivasankar$4,032,065
- Stephen Charles Kowalczykowski$30,504,074
- Gang-Yu Liu$1,304,543
Others in their field
Top investigators on “Mitochondria”
- Bruce M Spiegelman · Dana-Farber Cancer Inst$30,163,696
- Shi Du Yan · Columbia University Health Sciences$29,685,201
- Peipei Ping · University Of California Los Angeles$27,344,561
- Mary McGrae McDermott · Northwestern University$25,752,019
- Vamsi Krishna Mootha · Massachusetts General Hospital$23,004,991
- Kenneth D. Tew · Fox Chase Cancer Center$22,000,362
Research focus
MitochondriaCellsLongevityBaseAlzheimer&AposProteinsAgingMouse ModelInhibitor/AntagonistProgramsAnimal ModelTissuesDietInvestigationDoseIn VivoAge RelatedCell ModelPharmaceutical PreparationsMetabolismGenesMetabolicElderlyNerve Degeneration
Grant awards (75)
Investigations of targets, mechanisms, and optimal delivery of therapeutic ketosis for functional longevity and treatment of Alzheimer's disease$2,234,244
P01 · FY2023 · AG · contact PI
Elucidating biomarkers and mechanisms of the Ketogenic longevity mechanism$375,359
P01 · FY2023 · AG · contact PI
Administrative Core$225,002
P01 · FY2023 · AG · contact PI
Mitochondrial-mediated Lung Injury mechanisms of QACs in vivo$200,104
R21 · FY2023 · ES · contact PI
Investigations of targets, mechanisms, and optimal delivery of therapeutic ketosis for functional longevity and treatment of Alzheimer's disease$2,235,177
P01 · FY2022 · AG · contact PI
Targeting Shc to reduce inflammation and fibrosis in the aging liver$375,549
R01 · FY2022 · AG
Elucidating biomarkers and mechanisms of the Ketogenic longevity mechanism$375,359
P01 · FY2022 · AG · contact PI
'Novel Shc Blockers as potential Alzheimer's Disease Therapeutics$329,419
R41 · FY2022 · AG · contact PI
Mitochondrial-mediated Lung Injury mechanisms of QACs in vivo$239,313
R21 · FY2022 · ES · contact PI
Administrative Core$225,002
P01 · FY2022 · AG · contact PI
Investigations of targets, mechanisms, and optimal delivery of therapeutic ketosis for functional longevity and treatment of Alzheimer's disease$2,322,966
P01 · FY2021 · AG · contact PI
Elucidating biomarkers and mechanisms of the Ketogenic longevity mechanism$390,360
P01 · FY2021 · AG · contact PI
Targeting Shc to reduce inflammation and fibrosis in the aging liver$368,757
R01 · FY2021 · AG
'Novel Shc Blockers as potential Alzheimer's Disease Therapeutics$304,652
R41 · FY2021 · AG · contact PI
Administrative Core$220,379
P01 · FY2021 · AG · contact PI
Investigations of targets, mechanisms, and optimal delivery of therapeutic ketosis for functional longevity and treatment of Alzheimer's disease$2,236,723
P01 · FY2020 · AG · contact PI
Pharmacodynamics and in vivo efficacy of fumarate for mitochondrial disease in vivo$426,630
R33 · FY2020 · NS · contact PI
Elucidating biomarkers and mechanisms of the Ketogenic longevity mechanism$375,359
P01 · FY2020 · AG · contact PI
Targeting Shc to reduce inflammation and fibrosis in the aging liver$374,324
R01 · FY2020 · AG
Administrative Core$212,442
P01 · FY2020 · AG · contact PI
Investigations of targets, mechanisms, and optimal delivery of therapeutic ketosis for functional longevity and treatment of Alzheimer's disease$63,215
P01 · FY2020 · AG · contact PI
Investigations of targets, mechanisms, and optimal delivery of therapeutic ketosis for functional longevity and treatment of Alzheimer's disease$58,304
P01 · FY2020 · AG · contact PI
Investigations of targets, mechanisms, and optimal delivery of therapeutic ketosis for functional longevity and treatment of Alzheimer's disease$2,242,722
P01 · FY2019 · AG · contact PI
Friedreich's ataxia, mitochondrial biogenesis, and neurodegeneration$431,550
R21 · FY2019 · NS · contact PI
Elucidating biomarkers and mechanisms of the Ketogenic longevity mechanism$375,359
P01 · FY2019 · AG · contact PI
Targeting Shc to reduce inflammation and fibrosis in the aging liver$370,517
R01 · FY2019 · AG
Pharmacodynamics and in vivo efficacy of fumarate for mitochondrial disease in vivo$365,389
R21 · FY2019 · NS · contact PI
Administrative Core$212,442
P01 · FY2019 · AG · contact PI
A ketogenic longevity diet for resistance to age-related functional decline and Alzheimer's disease$783,430
R56 · FY2018 · AG · contact PI
Targeting Shc to reduce inflammation and fibrosis in the aging liver$371,200
R01 · FY2018 · AG
Pharmacodynamics and in vivo efficacy of fumarate for mitochondrial disease in vivo$367,706
R21 · FY2018 · NS · contact PI
SCHS, mitochondria, healthy aging and longevity$997,598
P01 · FY2017 · AG · contact PI
Mitofunction, Microarray and Screening for She inhibitors$250,872
P01 · FY2017 · AG · contact PI
Administrative Core$118,326
P01 · FY2017 · AG · contact PI
SCHS, mitochondria, healthy aging and longevity$1,004,189
P01 · FY2016 · AG · contact PI
MITOCHONDRIAL MECHANISMS IN OPTIC NEUROPATHY$448,373
R01 · FY2016 · EY · contact PI
Mitofunction, Microarray and Screening for She inhibitors$227,378
P01 · FY2016 · AG · contact PI
Administrative Core$107,291
P01 · FY2016 · AG · contact PI
SCHS, mitochondria, healthy aging and longevity$982,927
P01 · FY2015 · AG · contact PI
MITOCHONDRIAL MECHANISMS IN OPTIC NEUROPATHY$439,257
R01 · FY2015 · EY · contact PI
Mitochondrial Iron-Sulfur cluster mechanisms and therapy in Friedreich's ataxia$390,379
R01 · FY2015 · NS · contact PI
Mitofunction, Microarray and Screening for She inhibitors$229,705
P01 · FY2015 · AG · contact PI
Administrative Core$108,433
P01 · FY2015 · AG · contact PI
SCHS, mitochondria, healthy aging and longevity$1,021,935
P01 · FY2014 · AG · contact PI
Mitochondrial Iron-Sulfur cluster mechanisms and therapy in Friedreich's ataxia$386,687
R01 · FY2014 · NS · contact PI
MITOCHONDRIAL MECHANISMS IN OPTIC NEUROPATHY$377,300
R01 · FY2014 · EY · contact PI
Mitofunction, Microarray and Screening for She inhibitors$257,481
P01 · FY2014 · AG · contact PI
Administrative Core$121,813
P01 · FY2014 · AG · contact PI
MITOCHONDRIAL MECHANISMS IN OPTIC NEUROPATHY$62,925
R01 · FY2014 · EY · contact PI
SCHS, mitochondria, healthy aging and longevity$1,060,953
P01 · FY2013 · AG · contact PI
MITOCHONDRIAL MECHANISMS IN OPTIC NEUROPATHY$365,750
R01 · FY2013 · EY · contact PI
Mitochondrial Iron-Sulfur cluster mechanisms and therapy in Friedreich's ataxia$318,351
R01 · FY2013 · NS · contact PI
Administrative Core$176,827
P01 · FY2013 · AG · contact PI
Mitofunction, Microarray and Screening for She inhibitors$176,825
P01 · FY2013 · AG · contact PI
Mitochondrial Iron-Sulfur cluster mechanisms and therapy in Friedreich's ataxia$60,907
R01 · FY2013 · NS · contact PI
MITOCHONDRIAL MECHANISMS IN OPTIC NEUROPATHY$385,000
R01 · FY2012 · EY · contact PI
Mitochondrial Iron-Sulfur cluster mechanisms and therapy in Friedreich's ataxia$330,100
R01 · FY2012 · NS · contact PI
A Mitochondrial Longevity Pathway: P66Shc Mechanisms$1,412,778
P01 · FY2011 · AG · contact PI
PATHWAYS AND PARTNERS OF P66SHC: FUNCTIONAL GENOMICS$336,063
P01 · FY2011 · AG · contact PI
Mitochondrial Iron-Sulfur cluster mechanisms and therapy in Friedreich's ataxia$329,581
R01 · FY2011 · NS · contact PI
ADMINISTRATIVE CORE$130,662
P01 · FY2011 · AG · contact PI
A Mitochondrial Longevity Pathway: P66Shc Mechanisms$1,434,113
P01 · FY2010 · AG · contact PI
Mitochondrial iron-sulfur mechanisms in Friedreich's ataxia$373,587
R01 · FY2010 · AG · contact PI
PATHWAYS AND PARTNERS OF P66SHC: FUNCTIONAL GENOMICS$339,634
P01 · FY2010 · AG · contact PI
ADMINISTRATIVE CORE$132,407
P01 · FY2010 · AG · contact PI
A Mitochondrial Longevity Pathway: P66Shc Mechanisms$1,412,260
P01 · FY2009 · AG · contact PI
Mitochondrial iron-sulfur mechanisms in Friedreich's ataxia$373,490
R01 · FY2009 · AG · contact PI
PATHWAYS AND PARTNERS OF P66SHC: FUNCTIONAL GENOMICS$333,253
P01 · FY2009 · AG · contact PI
ADMINISTRATIVE CORE$130,277
P01 · FY2009 · AG · contact PI
A Mitochondrial Longevity Pathway: P66Shc Mechanisms$1,378,139
P01 · FY2008 · AG · contact PI
Mitochondrial Mechanisms in Optic Neuropathy$353,286
R01 · FY2008 · EY · contact PI
PATHWAYS AND PARTNERS OF P66SHC: FUNCTIONAL GENOMICS$330,330
P01 · FY2008 · AG · contact PI
FRIEDREICHS ATAXIA, MITOCHONDRIA AND CELL DEATH$269,078
R01 · FY2008 · AG · contact PI
ADMINISTRATIVE CORE$129,496
P01 · FY2008 · AG · contact PI
Mitochondrial Mechanisms in Optic Neuropathy$23,395
R01 · FY2008 · EY · contact PI